Sanjay Magavi

Sanjay Magavi, PhD, is Co-founder and the Chief Scientific Officer of Progentos Therapeutics. Previously, Sanjay led research efforts at Frequency Therapeutics as Vice president of Discovery Biology. Under Sanjay’s leadership the biology team discovered a novel target for remyelination, forming the basis for Progentos Therapeutics. 
 

Before working at Frequency Therapeutics, Sanjay was a Senior Director/Research Fellow II at Vertex Pharmaceuticals. He led the in vivo efforts on Vertex’s remyelination program, and initiated and led an adrenoleukodystrophy program through IND studies.  

Sanjay earned his Ph.D. in Neuroscience from Harvard University, where he studied under Jeffrey Macklis in the Department of Stem Cell and Regenerative Biology. Sanjay was a Postdoctoral Fellow at the Picower Institute for Learning and Memory at MIT and a Mirzayan Science Policy Fellow at the National Academy of Sciences. He earned a Sc.B. with Honors in Neuroscience from Brown University.